The in vitro assays for susceptibility of Plasmodium falciparum to antimalarial drugs are important tools for monitoring drug resistance. During the present study, efforts were made to establish long-term continuous in vitro culture of Indian field isolates of P. falciparum and to determine their sensitivity to standard antimalarial drugs and antibiotics.
Malaria remains one of the most widespread infectious diseases of the world. More than 85 per cent of malaria cases and 90 per cent of malaria deaths occur in Sub-Saharan Africa, mainly in young children below five years of age 1 . Incidences of chloroquine (CQ) resistance were first reported in the late 1950s from South-East Asia and South America 2 . In India, the first CQ-resistant Plasmodium falciparum case was documented in 1973 from the North-East Karbi -Anglong district of Assam 3 . In 1982, the National Antimalarial Drug Policy was introduced to improve malaria case management and sulphadoxine-pyrimethamine (SP) combination was recommended as the treatment for CQ-resistant malaria 4 . In November 1984, mefloquine (MQ) was introduced as the first-line treatment for uncomplicated falciparum malaria in Thailand, but despite careful regulation of its use, substantial resistance was developed within five years and emerged in adjacent countries, such as Burma and Cambodia 5 . Western Cambodia and Thailand-Myanmar border were the regions of greatest concern because resistance to both MQ and SP emerged in this area 6 . To overcome the problem associated with resistant falciparum malaria, artemisinin-based combination therapy (ACT), which included artesunate+MQ, artemether (ARTM)+lumefantrine (LUME) and artesunate+amodiaquine, was recommended as a first-line antimalarial treatment [7] [8] [9] [10] . However, the artemisinin class of drugs have also shown signs of reduced efficacy [11] [12] [13] [14] providing a potential threat to ACT. In 1994, two randomized trials were carried out in Western Cambodia (Pailin) and Northwestern Thailand (Wang Pha) by Dondorp et al 11 , who gave two regimens of artesunate treatment i.e. 2 mg/kg/day for seven days and 4 mg/kg/day for three days, followed by 25 mg/kg of MQ given in two doses. The results revealed that median parasite clearance times were 84 and 48 h in Pailin and Wang Pha, respectively, and recrudescence occurred in 30 per cent patients receiving artesunate monotherapy and in five per cent patients receiving artesunate-MQ combination therapy in Pailin, as compared with 10 and 5 per cent, respectively in Wang Pha. However, no reduction in in vitro susceptibility was observed by Dondorp et al 11 . Another long-term study 13 was carried out on 3202 patients in north-western border of Thailand. During this study, the patients received various artesunate-containing therapies between 2001 and 2010. The findings revealed that 'genetically determined artemisinin resistance in P. falciparum emerged along the Thailand-Myanmar border at least eight years ago and has increased substantially and may reach in Western Cambodia in 2-6 yr 13 . In 2012, Amaratunga et al 14 In vitro cultivation of parasite: Four field isolates (erythrocytic stages) were revived and maintained in 5 ml culture medium (RPMI-1640; Sigma, USA, R4130-1L) at 3 per cent haematocrit suspension [human red blood cells (RBCs)]. The culture medium was prepared as described elsewhere 22 . AlbuMAX-II (GIBCO, New Zealand; 11021/045) 0.5 and 10 per cent foetal bovine serum (FBS, Sigma, F2442/HYCLONE, SH30396.03HI) were used as serum supplements. The cultures were maintained stationary at 37°C in a CO 2 incubator (Thermo Electron Corporation, USA; water jacketed, model no. 3131) in the atmosphere of five per cent CO 2 and air mixture. The per cent parasitaemia (%P) was monitored daily. The in vitro culture of both reference strains was also maintained in the laboratory.
Assessment of per cent parasitaemia (%P):
The Giemsa-stained blood smears were examined under the light microscope (100×, oil immersion, Nikon, Japan). Approximately 10,000 RBCs per smear were scanned and %P was calculated as number of parasitized RBCs (PRBCs)/total number of RBCs × 100.
Assessment of growth profile of field isolates:
%P of all the parasites was monitored daily to determine the comparative growth profile of field isolates (MZR-I, MZR-II, MZR-III and MZR-IV) and reference parasite strains (3D7 and K1). Three replicates were carried out for each parasite isolate.
Assessment of chemosensitivity of field isolates:
Fifty and 90 per cent inhibitory concentration (IC 50 and IC 90 ) values of standard antimalarials and antibiotics were determined using malaria SYBR Green I fluorescence assay 23 and compared with those obtained against 3D7 and K1 parasites.
Drugs used: Chloroquine diphosphate (CQ), quinine hydrochloride dihydrate (QUIN), mefloquine hydrochloride (MQ), PPQ, ARTM, arteether (ARTE), DHA, LUME and atovaquone (ATQ) and antibiotics, azithromycin (AZI) and doxycycline (DOXY) were used for the assessment of chemosensitivity. CQ (C6628), QUIN (Q1125), MQ (M2319) and ATQ (A7986) were purchased from Sigma while PPQ, ARTM, ARTE, DHA and LUME were obtained (as gift) from IPCA Laboratories Ltd., Mumbai. The antibiotics were purchased from Biogene, USA.
Preparation of drugs:
Stock solutions (10 mM) of all the drugs was prepared in dimethyl sulphoxide (DMSO) except CQ and PPQ which were prepared in sterile water. The subsequent dilutions were prepared in CRPMI (RPMI-1640 with 10% FBS and 9.2 µM hypoxanthine). 50 and IC 90 values: CRPMI (50 µl) was dispensed in each well of 96-well flat bottom plate, followed by the addition of 50 µl test sample constituting 4× highest concentration in duplicate wells in row 'B' and 2-fold serial dilutions were made up to row 'H'. To obtain best-fit curve, highest concentrations of the same drug varied amongst parasite strains as depicted in Table I . The 50 μl volume from wells of row H was discarded. Subsequently, 50 µl of 2.0 per cent PRBCs suspension containing 1.0 per cent parasitaemia (with >90% ring stages) was added to each well, except four wells in row 'A' (A9-A12) which received two per cent non-parasitized cell suspension. The plates were incubated at 37°C in CO 2 incubator for 72 h. After which, 100 µl of lysis buffer containing 2× concentration of SYBR Green I was added to each well and incubated for one hour at 37°C. The plates were examined at 485±20 nm of excitation and 530±20 nm of emission for relative fluorescence units per well using the fluorescence plate reader (FLX 800 BIOTEK). The IC 50 and IC 90 values (in nM) were determined using non-linear regression analysis of dose-response curves using pre-programmed excel spreadsheet. The resistance factor of MZR-I, -II, -III and -IV parasites in respect to 3D7 and K1 strains was calculated as IC 50 values obtained against MZR parasites/IC 50 values obtained against 3D7 or K1 parasites.
Statistical analysis:
The data were analyzed by two-way ANOVA followed by multiple comparisons using Newman Keuls test (STATISTICA 7.0, StatSoft, USA) to establish significance between IC 50 and IC 90 values obtained against reference strains and MZR isolates.
Results
The continuous in vitro cultures of all the field isolates were successfully maintained in laboratory. Growth profile is depicted in Table II 
Discussion
A large number of studies have been carried out to observe in vitro susceptibility of both P. falciparum and P. vivax isolates to monitor drug resistance [25] [26] [27] [28] from different parts of the world, especially where CQ resistance is prevalent 29 . Wongsrichanalai et al 30 have observed the prevalence of high resistance to MQ in Thai-Myanmar border region. There are many consecutive reports claiming spread of Artemisinin ART resistance in Western Cambodia 11, 12, 14 and a recent report has provided evidence for the presence of artemisinin-resistant falciparum malaria across much of Upper Myanmar, close to the Indian border 20 . Artemisinins are the backbone of malaria therapy as these form the basis of ACTs where artesunate replaces quinine in the treatment of severe malaria 31, 32 . As these isolates showed tolerance to DHA-PPQ combination therapy, we planned to explore the in vitro susceptibility of these against existing antimalarials and commonly used antibiotics and observed significantly higher IC 50 (nM) and IC 90 (nM) values of CQ and quinine compared to reference strains. The increase in IC 50 and IC 90 values of DHA was not significant.
In conclusion, our findings showed that these field isolates of P. falciparum developed resistant to CQ and quinine but not to DHA as increase in IC 50 and IC 90 values of DHA were not significant. These findings indicated that the tolerance to DHA-PPQ combination might be because of PPQ only. Further study is required to establish a genetic correlation with high IC 50 and IC 90 values of CQ and QUIN.
